BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week

Core Insights - BullFrog AI Holdings, Inc. is participating in the TechBio track at Biotech Showcase and RESI JPM during the JP Morgan Healthcare Conference, showcasing its innovative approach to drug development using AI and machine learning [1] Group 1: Company Overview - BullFrog AI is a technology-enabled drug development company that utilizes artificial intelligence and machine learning to enhance the development of pharmaceuticals and biologics [1][6] - The company aims to revolutionize drug discovery and development by leveraging its proprietary bfLEAP™ platform and causal AI to analyze complex biological data [6] Group 2: Product Highlights - At the Biotech Showcase and RESI JPM, BullFrog AI will present its proprietary BullFrog Data Networks, a data insights tool that evaluates high-dimensional, multi-modal data in specific disease indications [2] - BullFrog Data Networks provide customized visual representations of previously unknown relationships and pathways, utilizing a variety of data inputs including publicly available datasets like the Human Cell Atlas, The Cancer Genome Atlas, and Gene Expression Omnibus [2] Group 3: Applications and Benefits - The BullFrog Data Networks address the challenge of transforming vast datasets into actionable insights, using machine learning to reveal hidden insights that traditional methods may miss [3] - The platform has demonstrated proof of concept in the company's research pipeline, focusing on colorectal cancer and neuropsychiatric indications, with applications in target identification, clinical trial optimization, and drug repurposing [4] - By accelerating the generation of novel insights, BullFrog Data Networks aim to reduce timelines and improve outcomes in drug development [4][5] Group 4: Development Lifecycle Support - The BullFrog Data Networks are designed to answer critical questions throughout the drug development lifecycle, from early target discovery to understanding drug safety and tolerability [5] - The networks can streamline development processes and optimize clinical trial design by identifying suitable patient populations for trials [5]